Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

ART's new generation Optix MX3 optical molecular imaging system unveiled

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today unveiled a new generation of its optical molecular imaging system, called Optix® MX3, at the Industry Workshop opening event of the World Molecular Imaging Congress.

23 Sep 2009

Agilent Technologies and Applied Biosystems to co-market SureSelect system

Agilent Technologies Inc. (NYSE:A) and Applied Biosystems, part of Life Technologies Corp. (NASDAQ:LIFE), today introduced the Agilent SureSelect Target Enrichment System, which is optimized for the SOLiD™ System, a next-generation advanced genomic analysis sequencing platform.

23 Sep 2009

Norman Noble to use Raydiance Corporation's Smart Light ultrafast platform

Raydiance Corporation, developer of the world’s first commercial-grade ultrafast laser, announced today that its Smart LightTM ultrafast platform will provide the core technology for an advanced laser machining process, Noble UltraLightTM, to be launched by leading contract manufacturer Norman Noble, Inc. The Noble UltraLightTM process will enable highly precise, athermal machining of bio-absorbable materials, shape memory metals and other exotic materials for the medical device industry.

23 Sep 2009

StemCells pushing forward its SC Proven cell culture product business

StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company’s ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company’s Cambridge, UK and Palo Alto, California locations.

23 Sep 2009

NIST collaborates with private industry to release a new reference material for beryllium

Researchers at the National Institute of Standards and Technology (NIST), in collaboration with private industry and other government agencies, have produced a new reference material for beryllium. Beryllium, an exotic rare-earth metal used as a hardener in high-performance alloys and ceramics, can cause berylliosis-a chronic, incurable and sometimes fatal illness.

23 Sep 2009

Fourth-quarter and fiscal year end 2009 results announced by Natural Alternatives International

Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced a net loss of $4.1 million or $0.58 per diluted share on net sales from continuing operations of $73.9 million for the fiscal year ended June 30, 2009.

23 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Preclinical data on Protalix Biotherapeutics' antiTNF released

Protalix Biotherapeutics, Inc., reported today preclinical data on pr-antiTNF, a biosimilar version of etanercept (Enbrel). Produced using the Company’s proprietary ProCellEx technology, pr-antiTNF is a plant cell expressed recombinant fusion protein made from the soluble form of the human TNF receptor (TNFR), fused to the Fc component of a human antibody IgG1 domain. Pr-antiTNF has an identical amino acid sequence to Enbrel.

23 Sep 2009

U.S. FDA bans flavored cigarettes

One of the first provisions of the new federal law regulating tobacco products will take effect Tuesday as the U.S. Food and Drug Administration (FDA) enforces a ban on candy, fruit and other flavored cigarettes.

22 Sep 2009

Sanofi Pasteur receives additional order H1N1 vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the company has received an additional order from the U.S. Department of Health and Human Services (HHS) to produce vaccine to help protect against the Influenza A (H1N1) 2009 virus. The new order is for the production of bulk antigen equivalent to 27.3 million doses based on 15 mcg of antigen per dose.

22 Sep 2009

Updates from Pacific Biosciences to its commercial strategy and progress

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today provided a number of updates to its commercial strategy and progress.

22 Sep 2009

Breast Cancer Action launches "Milking Cancer" campaign against Eli Lilly

Breast Cancer Action (BCA), known as the watchdog of the breast cancer movement, today announced the launch of their "Milking Cancer" campaign challenging the pharmaceutical giant Eli Lilly to stop manufacturing rBGH. rBGH (recombinant bovine growth hormone, also known as rBST) has long been linked to cancer.

22 Sep 2009

Gerresheimer opens new R&D and production centers in USA and Europe

The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe. This week the company is almost simultaneously opening a new research and development center for medical plastic systems in the USA as well as a new production center for pharmaceutical plastic packaging in Spain.

22 Sep 2009

Gerresheimer opens new R&D and production centers in USA and Europe

The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe.

22 Sep 2009

Industrial lipases launched by EUCODIS Bioscience

EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has launched the first enzymes of its lipase portfolio. EUCODIS Bioscience currently offers 12 lipases that have been selected to cover a broad range of potential industrial applications.

22 Sep 2009

Dalton Pharma expands pharmaceutical manufacturing services

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

22 Sep 2009

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.

22 Sep 2009

Cydex Pharmaceuticals announces extension of agreement with Hovione

CyDex Pharmaceuticals, Inc. today announced the extension of its relationship with Hovione SA as the company’s exclusive supplier of Captisol® for an additional five years.

21 Sep 2009

Manhattan Scientifics inks exclusive licensing contract with Carpenter Technology

Manhattan Scientifics, Inc. (OTCBB: MHTX) announced the signing of a contract with Carpenter Technology Corporation (NYSE: CRS), wherein Carpenter will fully develop, manufacture and market a new class of high strength metals under an exclusive license from Manhattan Scientifics and the Los Alamos National Laboratory. The contract includes minimum annual payments to Manhattan Scientifics during a 4-year period, together with royalty payments as a percent of gross sales.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009